Efgartigimod
Efgartigimod is designed as a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn). Efgartigimod is being evaluated for the treatment of patients with severe autoimmune diseases with confirmed presence of pathogenic immunoglobulin G, IgG autoantibodies, where a severe unmet medical need exists.
Neurology
Hematology / Rheumatology
Dermatology
Nephrology
Indication not disclosed
Program
Clinical trial
Preclinical
Phase 1
Proof of Concept
Registrational
Commercial
Primary Immune Thrombocytopenia (ITP)
- Primary ITP is a rare, often chronic disorder where IgG antibodies cause reduced numbers of platelets leading to an increased risk of bleeding and bruising
- IV efgartigimod and SC efgartigimod
Seronegative gMG
Ocular Myasthenia Gravis (oMG)
Thyroid Eye Disease (TED)
Bullous Pemphigoid (BP)
Myositis (IMNM, ASyS, DM)
Sjogren's Disease
Membranous Nephropathy (MN)
Lupus Nephropathy (LN)
Systemic Sclerosis
Antibody Mediated Rejection (AMR)
Clinical trials
argenx is running clinical trials of efgartigimod, in development for a range of severe autoimmune diseases. For more info on clinical trials with efgartigimod, please click the link below.
Proposed
Mechanism
of Action
